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Daily supplementation 
with the Lab4P probiotic 
consortium induces significant 
weight loss in overweight adults
D. R. Michael1*, T. S. Davies1, A. A. Jack1, G. Masetti1,5, J. R. Marchesi2,3, D. Wang4, 
B. H. Mullish3 & S. F. Plummer1
This 9-month randomised, parallel, double-blind, single-centre, placebo-controlled study (PROBE, 
ISRCTN18030882) assessed the impact of probiotic supplementation on bodyweight. Seventy 
overweight Bulgarian participants aged 45–65 years with BMI 25–29.9 kg/m2 received a daily dose 
of the Lab4P probiotic comprising lactobacilli and bifidobacteria (50 billion cfu/day). Participants 
maintained their normal diet and lifestyle over the duration of the study. The primary outcome 
was change from baseline in body weight and secondary outcomes included changes in waist 
circumference, hip circumference and blood pressure. A significant between group decrease in 
body weight (3.16 kg, 95% CI 3.94, 2.38, p < 0.0001) was detected favouring the probiotic group. 
Supplementation also resulted in significant between group decreases in waist circumference 
(2.58 cm, 95% CI 3.23, 1.94, p < 0.0001) and hip circumference (2.66 cm, 95% CI 3.28, 2.05, p < 0.0001) 
but no changes in blood pressure were observed. These findings support the outcomes of a previous 
shorter-term Lab4P intervention study in overweight and obese participants (PROMAGEN, 
ISRCTN12562026). We conclude that Lab4P has consistent weight modulation capability in free-living 
overweight adults.
The gastro-intestinal (GI) microbiota is a contributor to human health and has been implicated in many meta-
bolic processes including the digestion and absorption of nutrients and the fermentation of undigested car-
bohydrates into short chain fatty acids and other  metabolites1. The link between dysbiosis and obesity is well 
recognised but nearly 40% of the adults worldwide are categorised as  overweight2 and this population gains 
on average 0.2–1.0 kg/year3. In addition to progressive weight gain, the aging process itself is characterised by 
changes in the gut microbiota and the development of a chronic inflammatory  status4 which is linked to weight 
associated comorbidities such as diabetes, cardiovascular disease and  cancer5,6. Consequently, attention is being 
drawn to the potential for modulation of these changes as an additional approach in the battle against obesity.
The World Health Organisation (WHO) defines probiotic bacteria as ‘live microorganisms that, when admin-
istered in adequate amounts confer a health benefit on the host’7, and there is accumulating evidence supporting 
their impact on the gut microbiota resulting in beneficial  effects8–10. Recent meta-analyses report that body weight 
reductions have been achieved in short-term probiotic intervention studies (averaging 2 months) in overweight/
obese  particpants11–13. It is considered that a 3% reduction in bodyweight over a 6–12 month period represents 
successful weight  loss14 whilst current clinical guidelines state that a 5% reduction is required to illicit significant 
improvements in  health15.
In an exploratory placebo-controlled study (PROMAGEN, ISRCTN12562026) the impact of supplementa-
tion with the Lab4P probiotic consortium in overweight and obese adults with no dietary or lifestyle restrictions 
resulted in a significant reduction in body weight (1.5%) over a 6-month period together with improvements in 
quality-of-life and reductions in the incidence of upper respiratory tract  infections16. Stratification of the study 
population indicated greater weight losses in older participants (2% compared to ≤ 1.2% in younger participants) 
and with 1.9% weight reduction in overweight participants compared to 1.2% in obese  participants16. The design 
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of the current study was based on the findings from the PROMAGEN study. This study’s aim was to repeat the 
assessment of the PROMAGEN probiotic supplementation specifically in overweight, older participants, measur-
ing body weight (BW), waist circumference (WC), hip circumference (HC) and blood pressure (BP).
Methods
Study approval. This study was a single-centre, double-blind, randomised and placebo-controlled superi-
ority study with equal allocation of participants between two parallel study groups. The study was approved by 
the Ethical Committee of Comac Medical, Sofia, Bulgaria (Reference: #168/08.05.2019), registered with IRSCTN 
(ISRCTN18030882, Registration date: 27.11.2019) and was conducted in accordance with the principles of the 
Declaration of Helsinki.
Recruitment, participants and randomisation. The trial was performed by Comac Medical Ltd and 
healthy Bulgarian adults (aged 45–65; BMI 25–29.9  kg/m2; WC > 89  cm for women and > 100  cm for men) 
providing written informed consent were recruited at a trial facility (Sofia, Bulgaria) between 17/05/2019 and 
22/05/2019.
Sample size calculations were based on the body weight changes observed in a subgroup of PROMAGEN 
participants (aged 45–65, BMI 25–29.9 kg/m2) and 31 participants per group were required to detected a 1.54 kg 
reduction (standard deviation of 2.01 kg) using a Type I error of 0.05 and a power of 85%. Thirty-five participants 
per group were selected to account for potential drop-outs.
Participants were excluded if they were undergoing immunodeficiency/immunosuppressive therapy; pregnant 
or planning pregnancy; had history of ischemic heart disease, heart failure, prolonged QTc interval, rhythm 
and conduction disorders—absolute arrhythmia, ventricular extrasystole, atrioventricular block or any other 
cardiovascular disease deemed by the investigator as a risk for the participation in the study; had severe systemic 
disease (cancer, dementia, advanced organ failure); had experienced significant weight loss in the last 3 months 
that could not be explained by a dietary regimen or increased physical activity; or if they had received any statin 
therapy in the 6 months prior to the study period.
All participants were sequentially allocated to one of two arms of the study in a 1:1 ratio according to a 
computer-generated random sequence (block-size of four using SAS PROC PLAN (SAS version 9.4)). An inde-
pendent statistician provided the randomisation code and the trial product was randomised before arrival at the 
trial site. The allocation sequence was not made available to researchers until all databases were completed and 
locked (the allocation sequence was held at the trial site in tamper-proof sealed envelopes in case of emergency).
Study design and intervention. The randomised participants received one capsule per day of either the 
active Lab4P product or a matching placebo for 9  months (270  days). Participants were advised to take the 
intervention with food (with or without a cool drink) at any time of day within no less than 2 h of any antibiotic 
intake. All participants were required to avoid the consumption of any probiotics and maintain their normal diet 
and lifestyle throughout the study.
The active product (Lab4P) was identical to that used in  PROMAGEN16 and comprised Lactobacillus aci-
dophilus CUL60 (NCIMB 30157), Lactobacillus acidophilus CUL21 (NCIMB 30156), Lactobacillus plantarum 
CUL66 (NCIMB 30280), Bifidobacterium bifidum CUL20 (NCIMB 30153) and Bifidobacterium animalis subsp. 
lactis CUL34 (NCIMB 30172) at a total of 5 × 1010 colony forming units (cfu) per capsule. The placebo capsules 
comprised microcrystalline cellulose and were identical in appearance to the active product. All capsules were 
prepared by Cultech Ltd, Port Talbot, UK and were provided in induction-sealed pots. The trial products were 
stored between 4 and 8 °C at the trial site and participants were required to refrigerate the intervention through-
out the study. Unused capsules were collected for compliance monitoring.
Study outcomes. The primary outcome was change from baseline in body weight (BW). Secondary out-
comes were changes from baseline in waist circumference (WC), hip circumference (HC) and blood pressure 
(BP). Other secondary outcomes are not included in this report.
Data and sample collection. Participants were required to attend the study centre on four occasions: 
Baseline (day 0), 3 months (day 90 ± 3), 6 months (day 180 ± 3) and 9 months (day 270 ± 3). The height of par-
ticipants was recorded at baseline and BW, WC, HC and BP were measured at all visits. Pots of 93 capsules 
were provided to participants at the baseline, 3 and 6 month visits and unused capsules collected at the 3, 6 and 
9 month visits.
Physiological measurements. All physiological measurements were made as previously  described16. 
Briefly, BW was recorded using a calibrated column scale (Seca 709, Hamburg, Germany) after the removal of 
shoes and jackets; WC was measured 2 fingers below the umbilicus; HC was measured at the level of maximum 
protrusion; seated BP was measured after 5  min respite using a calibrated blood pressure monitor (Omron, 
Kyoto, Japan) and height was measured after the removal of shoes. The time at which measurements were taken 
was standardised for each participant wherever possible.
Data management and statistical analysis. Data was analysed as previously  described16. Briefly, anal-
ysis of study outcomes was performed on an intention-to-treat basis using a linear mixed model (LMM) that 
included treatment, time and interaction between treatment and time as fixed effects, baseline measurements 
as the covariate and subject as the random effect. Differences between treatment groups at each time point 
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with 95% confidence intervals (CI) from a t-test were calculated from the LMM. Covariate adjusted analyses 
within the LMM framework as described above were performed on all outcomes with age, gender and BMI as 
covariates. Values of p were considered statistically significant when less than 0.05. Continuous variables were 
summarised using mean ± standard deviation (SD). Data analyses were performed using SAS version 9.4 (SAS 
Institute Inc., Cary, NC, USA).
Results
Recruitment. Eighty-one conforming candidates were identified from a database of healthy participants 
and 70 of these participants were recruited. The study took place between May 2019 and February 2020 and there 
were no drop-outs, exclusions or adverse events in either arm of the study (Fig. 1). Compliance to the interven-
tion (as defined by number of returned capsules) exceeded 99% in both arms of the study.
Physiological measurements. Baseline demographics of the participants are shown in Table 1. Changes 
in BW, BMI, WC and HC are shown in Fig. 2 (detailed data presented in Supplementary Table S1). Significant 
between group reductions in BW compared to the placebo were seen at 3 months (− 2.51%, − 2.11 kg, p < 0.0001), 
6 months (− 2.19%, − 1.88 kg, p < 0.0001) and 9 months where weight loss approached 4% (− 3.76%, − 3.16 kg, 
p < 0.0001, Fig. 2a). Weight loss from baseline for the probiotic group was consistent and reached significance 
at 3 months (− 2.83%, − 2.37 kg, p < 0.0001), 6 months (− 4.00%, − 3.35 kg, p < 0.0001) and 9 months (− 4.36%, 
− 3.65 kg, p < 0.0001). Significant weight loss was recorded in the placebo group at 6 months (− 1.81%, − 1.47 kg, 
p < 0.0001), but the weight of the participants in the placebo group returned to near baseline by 9  months. 
Changes in BMI over the course of the study were consistent with weight loss results (Fig. 2b).
The weight loss was reflected in significant between group reductions in both WC and HC in response to the 
probiotic at each time point and by 9 months had dropped by 2.48% (− 2.58 cm, p < 0.0001, Fig. 2c) for WC and 
2.36% (− 2.66 cm, p < 0.0001, Fig. 2d) for HC. These changes contributed to significant reductions in the waist-
to-height ratio (WtHR) and the conicity index (WC (cm)/(0.109
√
BW(kg)/Height (m)))17 in the probiotic group 
(Supplementary Table S1). No changes in systolic or diastolic blood pressure were recorded during the study.
Rates of successful weight loss (SWL) and clinical weight loss (CWL). Figure 3 clearly indicates 
consistency of the weight loss in the active group with 33/35 participants achieving weight loss by 9 months 
(Fig.  3a). In the placebo group there was little weight loss in the first 6  months, and then weight regain at 
9 months (Fig. 3b). At the end of the study, six participants from the active group moved from overweight BMI 
status to healthy BMI status (< 24.9 kg/m2) compared with two participants in the placebo group (Fig. 3c). Three 
participants in the placebo group progressed into the obese BMI status (≥ 30 kg/m2) but none in the active group.
The distribution of percentage weight change can be seen in Fig. 3d. In the early stages of the study all par-
ticipants lost or maintained weight (except one in the placebo group) with greater percentage weight losses in 
Figure 1.  Flow diagram of study.
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the active group. A weight loss of ≥ 3% (considered “successful” weight loss by Grembi et al.14) was achieved by 
17/35 active group participants and 0/35 placebo group participants after 3 months supplementation (49% vs. 
0% respectively, p < 0.0001, Figs. 3d, 4). By 9 months more than 70% of the active group had achieved 3% weight 
loss compared with less than 20% of the placebo group (71% vs. 17% respectively, p < 0.0001).
In both groups there were instances where weight loss had reached levels that could be considered clinically 
meaningful (defined as 5% weight loss over a 6–12 month  period15) and these reductions were more prevalent 
in the active group compared to the placebo at both 6 months (31% vs. 6%, p = 0.0071) and 9 months (40% vs. 
3%, p = 0.0002).
Table 1.  Demographic and baseline characteristics of the PROBE population. The data represents the 
mean ± standard deviation (SD) of 35 participants in each group. The number of participants (n) that were 
male or female in each group are expressed as a percentage of the total group size. BMI body mass index, WC 
waist circumference, HC hip circumference, SBP systolic blood pressure, DBP diastolic blood pressure, WtHR 
waist-to-height ratio, WC:HC waist-to-hip ratio.
Active (n = 35) Placebo (n = 35)
Mean (SD) Mean (SD)
Study demographics
Age (years) 52.40 (5.84) 55.26 (5.79)
Males (n (%)) 18 (51.4%) 19 (54.3%)
Females (n (%)) 17 (48.6%) 16 (45.7%)
Anthropometry
Weight (kg) 83.66 (11.26) 81.16 (11.24)
Height (m) 1.72 (0.10) 1.70 (0.10)
BMI (kg/m2) 28.10 (1.55) 27.90 (1.54)
WC (cm) 104.20 (9.60) 106.37 (11.93)
HC (cm) 112.40 (6.65) 111.06 (7.25)
SBP (mmHg) 127.11 (10.45) 129.49 (9.56)
DBP (mmHg) 81.00 (7.04) 84.26 (6.75)
WtHR 0.61 (0.05) 0.63 (0.06)
WC:HC 0.93 (0.09) 0.96 (0.09)
Conicity Index 1.37 (0.10) 1.42 (0.14)
Figure 2.  Changes from baseline in (a) body weight, (b) BMI, (c) waist circumference and (d) hip 
circumference over the duration of the intervention period. Data is presented as mean change from baseline (35 
participants per group) with 95% CI and p values calculated using a LMM. For within group comparisons (vs. 
baseline): **p ≤ 0.01 and ***p ≤ 0.001. For between group comparisons (active vs. placebo): ###p ≤ 0.001.
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Figure 3.  Absolute changes in body weight for each participant in the (a) active group or (b) placebo group 
over the duration of the study and the distribution of changes in participant (c) BMI and (d) percentage change 
in body weight. Data is presented for 35 participants per group.
Figure 4.  The number of participants achieving successful weight loss and clinical weight loss after 3 months, 
6 months and 9 months. Data is presented for 35 participants per group. SWL successful weight loss, CWL 
clinical weight loss. Diagram created using sankeyMATIC (http://sanke ymati c.com/faq/).
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Discussion
Daily supplementation of a free-living population of healthy overweight individuals aged 45–65 with the Lab4P 
probiotic for 9 months resulted in a significant reduction in body weight of 3.8% together with a 2.5% reduction 
in waist circumference and a 2.4% reduction in hip circumference. No significant changes in blood pressure 
were detected.
In our previous 6-month exploratory study assessing the impact of the Lab4P probiotic (PROMAGEN) in 
free-living overweight and obese adults, weight-loss was identified as a significant  outcome16. At 6 months, sig-
nificant body weight reductions were seen in the probiotic treated group compared to the placebo (− 1.30 kg, 95% 
CI − 1.77, − 0.83, p < 0.0001) and sub-group analysis of the population revealed the highest weight losses in par-
ticipants aged 50 or over (2% reduction, p = 0.0002) or in the overweight category (1.9% reduction, p < 0.0001)16. 
In the meta-analysis of Koutnikova et al., greater levels of probiotic-mediated weight loss were observed in 
overweight participants compared to the  obese11. Although much attention is focused on obese individuals, it is 
estimated that about 70% of adults in England aged between 45 and 65 are classified as  overweight18 and these 
people need support to prevent their progression into an obese state due to the anticipated annual weight  gain3.
PROBE was designed as the follow-up to the PROMAGEN study with the aim of confirming the probiotic-
associated weight losses observed in overweight  adults16 and significant reductions in body weight occurred in 
the absence of any restrictions imposed on daily diet or lifestyle. Studies demonstrating consistent probiotic-
mediated weight loss are extremely rare with existing reports limited to Asian populations and the results of these 
are  variable19–22. Numerous meta-analyses have attempted to estimate the overall probiotic weight loss effect from 
studies with highly variable designs (many with lifestyle/dietary restrictions), interventions (strain and dose) and 
target populations and have reported reductions in the region of 0.5–1%11,23 or no  effect12,24. We are one of the 
first groups to demonstrate a consistent weight loss effect across two studies in free-living western populations.
The intervention period in the PROBE study was extended to 9 months to identify if the weight changes 
observed over the 6-month period in the PROMAGEN study might be on-going. We found that weight loss 
continued up to 9 months at which point the between group difference in body weight approached 3.2 kg (~ 7 lb). 
Clinically meaningful levels of weight loss are defined as a 5% reduction in body weight over a 6–12 month period 
and are associated with measurable metabolic benefits (such as improvements in glycaemic index and plasma 
lipid levels) and reduced healthcare  costs15,25. Using ≥ 5% weight loss as a potentially beneficial reference point, 
40% of the Lab4P treated group reached this “clinical” target after 9 months supplementation compared to only 
3% of participants in the placebo group.
In both the PROBE and PROMAGEN studies, the intervention period spanned Christmas and New Year 
and weight gains of 0.4–1.0 kg have been observed in the general population over this  period3. In the PROBE 
study, the placebo group gained weight during this period (between 6 to 9 months), and this gain counterbal-
anced the overall weight losses observed in the first 6 months. However, modest weight loss was maintained in 
the probiotic group through this period. This difference raises the possibility that Lab4P supplementation may 
help prevent the weight regain observed in the placebo group after weight loss that is a near-ubiquitous problem 
driven by physiological, psychological and environmental  factors26. It has been found that more than half of the 
weight lost by an individual is regained within 2 years of the initial weight  loss27.
The PROBE study reiterated the observed reduction in waist circumference in the PROMAGEN study and 
also demonstrated a reduction of hip circumference and the waist/hip ratio. These criteria are used to assess 
abdominal (central) obesity and elevated waist/hip measurements, and have been linked to the development of 
cardiovascular  disease28,29 and  dementia30.
Numerous mechanisms of action for probiotic-mediated weight loss have been proposed. These include the 
deconjugation of bile acids by bacterial bile salt hydrolases (BSH) which has been shown to impact on a num-
ber of key physiological processes in the host including lipid  metabolism31,32. Studies in vitro with the Lab4P 
probiotics indicate that this consortium expresses BSH  activity33,34 and functionality was confirmed in mouse 
studies where Lab4P treated C57BL/6 mice had increased faecal levels of deconjugated bile acids that occurred 
alongside the inhibition of high fat diet induced weight  gain34. In the PROMAGEN study with adults, an associa-
tion between the weight loss and high baseline faecal levels of sulphated bile acids was identified, leading us to 
conclude that host physiology may also be a contributory factor influencing the probiotic associated weight  loss35.
The strengths of our study include the powered sample size, the 9-month intervention period and the unad-
justed lifestyle conditions, that give our findings applicability to the ‘real world’ setting. The limitations of our 
study include the initial weight loss observed in the placebo group although this did not persist over the entirety 
of our study and the placebo effect has become a recognised feature of obesity  research36. The specific BMI range 
and single geographical isolation of our study population provides uniformity and continuity on one hand but 
requires further work in both obese and ideal weight participants and in another setting.
In summary, the PROBE intervention study has demonstrated that 9 months Lab4P supplementation at 
5 × 1010 cfu/day significantly reduced bodyweight, BMI, waist circumference and hip circumference in a free-
living overweight population aged 45–65 years old. These results agreed with the outcomes a previous exploratory 
study and highlight the potential for a role for probiotic supplementation within the weight management arena.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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